NCT01794429View on ClinicalTrials.gov

Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue

PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
ObesityMetabolic Syndrome XDrug-induced ObesitySchizophrenia
Interventions
DRUG

Exenatide

Subcutaneum injection of exenatide once-weekly for 3 months

DRUG

Placebo

Subcutaneum injection of placebo once-weekly for 3 months

Trial Locations (1)

2600

Cnsr/Cins, Glostrup Municipality

All Listed Sponsors
lead

Bjorn H. Ebdrup

OTHER

NCT01794429 - Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue | Biotech Hunter | Biotech Hunter